Quince Therapeutics (QNCX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Quince Therapeutics, Inc. has enhanced its board by appointing Rajiv Patni as a Class III director, effective February 15, 2024, with his term set to conclude at the 2025 Annual Meeting of Stockholders. Patni will receive the standard compensation for outside directors, including a $38,000 annual retainer and a stock option award for 54,000 shares, which vests over three years. Additionally, the company has provided Patni with an indemnification agreement to cover legal expenses related to his directorial role. Mr. Patni has no disclosed familial ties with other directors or significant transactions that could present a conflict of interest.
For further insights into QNCX stock, check out TipRanks’ Stock Analysis page.